Base Year
Historical Year
Forecast Year
The global monoclonal antibodies market size was valued at USD 210.6 billion in 2023, driven by the rising prevalence of chronic and infectious diseases across the globe. The market is expected to grow at a CAGR of 11.5% during the forecast period of 2024-2032, with the values likely to rise from USD 234.9 billion in 2024 to USD 562.8 billion by 2032.
Monoclonal antibodies have therapeutic potential as they carry the ability to enhance, restore, modify, or mimic the immune system’s attack on certain unwanted cells, like cancer cells. They are a form of targeted drug therapy that is administrated intravenously. The rising prevalence of chronic diseases and infectious diseases drives the need for effective monoclonal antibody therapies to treat various medical conditions.
The global burden of chronic diseases is rapidly increasing which is expected to bolster the monoclonal antibodies market growth in coming years. According to the World Health Organisation (WHO), chronic diseases account for 41 million deaths annually. It is further estimated that cancer and diabetes cause 9.3 million and 2 million deaths per year, respectively. Monoclonal antibodies, with their ability to target disease mechanisms, can offer a promising treatment solution to combat these rising cases of global mortality due to chronic disease.
The market is witnessing increased strategic partnerships, collaborations, and research and development (R&D) investments from various public and private organizations. In September 2023, the United States Department of Health and Human Services (HHS) announced an extension of its partnership with Regeneron Pharmaceuticals. The agreement, valued at USD 326 million, is expected to support the development of a next-generation monoclonal antibody for COVID-19 prevention and is a part of HHS’s Project NextGen. The contract states that the list price of the new product if commercialized, should either be equivalent to or lesser than its approved price in comparable markets globally. Such public-private partnerships are anticipated to greatly impact the monoclonal antibodies market size in the forecast period.
Other factors that influence the market dynamics include the growing adoption of monoclonal antibody therapies in the healthcare sector, heightened patient awareness, and improvements in the regulatory landscape which enables the availability of new therapeutic options in the markets. Moreover, the rise in research initiatives aimed at developing innovative monoclonal antibody therapies is likely to augment the market size.
| Key Trend | Impact |
| Rapid Technological Advancements | Technological advancements in biotechnology and genetic engineering have fuelled the development as well as the production of monoclonal antibodies (mAbs). Innovations like recombinant DNA technology, hybridoma technology, and phage display have improved the specificity and efficacy of monoclonal antibodies against their targets. This trend expands monoclonal antibody applications across a wide range of diseases, including cancer, autoimmune diseases, and infectious diseases, and helps in attracting significant research and development investment. |
| Growing Demand for Personalized Medicine | The growing demand for personalized medicine and the increasing emphasis on understanding the genetic basis of diseases have made a significant impact on the market. Monoclonal antibody therapies can be tailored to individual patient profiles, based on genetic markers and disease characteristics. Such customization opportunities can improve treatment outcomes and reduce side effects, driving the monoclonal antibodies market demand to facilitate a targeted approach in therapy development. |
| Improvements in Regulatory Framework | Supportive regulatory environments such as fast-track designations, orphan drug status, and breakthrough therapy designations, have greatly impacted the market. Such regulatory reforms accelerate the approval process for promising monoclonal antibody therapies. This also encourages pharmaceutical companies to invest in the development of monoclonal antibodies for unmet medical needs of patients across the world. Moreover, the evolving regulatory framework speeds up the availability of innovative treatments to patients. |
| Expansion into Emerging Markets | The rising healthcare expenditures, improving healthcare infrastructure, and growing public awareness of advanced therapies have accelerated the expansion of the monoclonal antibodies market share into emerging economies. These emerging markets offer potential for monoclonal antibodies due to their large patient populations and increasing incidence of diseases treatable by the therapeutic. Further, key market players are strategically entering these markets, thus driving market growth and accessibility to monoclonal antibodies therapies. |
Market Breakup by Production Type
The market segmentation by production includes in vitro and in vivo production methods. This market segment illustrates the different approaches utilized to produce monoclonal antibodies.
Market Breakup by Application
Monoclonal antibodies are utilized in various therapeutic areas including oncology, autoimmune diseases, infectious diseases, neurological diseases, and others, addressing a wide range of medical conditions. The applications of monoclonal antibodies are rapidly expanding to treat a range of chronic and infectious diseases. This increased use is expected to augment the market scope and elevate monoclonal antibodies market value.
Market Breakup by End User
End-users of monoclonal antibodies include hospitals, and specialty clinics, among others. These healthcare facilities provide access to these biologic agents for diverse patient populations and clinical needs.
Market Breakup by Region
The monoclonal antibodies market analysis offers insights into major regional markets such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America leads the market segment which can be attributed to the presence of an advanced healthcare infrastructure along with heightened patient awareness which enables more people to seek monoclonal antibody treatment options. Further, the rise in the prevalence of chronic diseases, with recent data suggesting that 6 in 10 Americans are affected by at least 1 chronic disease , directly impacts the market demand in the region.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Production Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 210.6 billion in 2023 driven by the rising prevalence of chronic and infectious diseases.
The market is anticipated to grow at a CAGR of 11.5% during the forecast period of 2024-2032, likely to reach a market value of USD 562.8 billion by 2032.
Heightened patient awareness and increased healthcare expenditure are fuelling the demand for the market.
One of the significant trends in the market is increased strategic partnerships, collaborations, and research and development investments from various public and private organizations. In September 2023, the United States Department of Health, and Human Services (HHS) announced its partnership extension with Regeneron Pharmaceuticals. Valued at USD 326 million, the agreement is anticipated to support the development of a next-generation monoclonal antibody for COVID-19 prevention.
Based on the production type, the market is segmented into in vitro and in vivo production methods.
End-users of monoclonal antibodies include hospitals, and specialty clinics, among others.
Applications of monoclonal antibodies include oncology, autoimmune diseases, infectious diseases, neurological diseases, and others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Novartis AG, Pfizer Inc., GlaxoSmithKline PLC, Merck & Co. Inc, Daiichi Sankyo Company, Limited, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Johnson & Johnson, Bristol Myers Squibb, F. Hoffmann La Roche Ltd., Biogen Inc., Sanofi, and Novo Nordisk A/S.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share